Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Palvella Therapeutics, retaining the price target of $90.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky has given his Buy rating due to a combination of factors, primarily focusing on Palvella Therapeutics’ innovative approach and strategic development plans. The company has introduced its first non-rapamycin QTORIN platform product, QTORIN pitavastatin, which is an FDA-approved statin targeting the mevalonate pathway. This product is being developed for disseminated superficial actinic porokeratosis (DSAP), a rare dermatological condition with no current FDA-approved treatments, presenting a significant market opportunity with over 50,000 diagnosed patients in the U.S.
Palvella’s strategy to be a first-in-disease and standard-of-care provider in commercially attractive markets aligns with its broad pipeline approach. The company is planning an FDA meeting in the first half of 2026 to discuss a Phase 2 trial, with initiation expected in the second half of 2026. The estimated cost to reach Phase 2 proof-of-concept data is approximately $10 million, reflecting Palvella’s careful capital management in R&D. The encouraging preliminary data on drug stability and dermal penetration capabilities, along with multiple IP filings, further support the potential of QTORIN pitavastatin, making it a compelling investment opportunity.
In another report released today, Stifel Nicolaus also reiterated a Buy rating on the stock with a $87.00 price target.